NRF1

Across TCGA pan-cancer cohorts, NRF1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NRF1 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher NRF1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NRF1 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

DLBC, BRCA, and BLCA are the cancer types where NRF1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
BRCA	OS	Median	II,III,IV	0.350	0.913	<.001	26	view →
BLCA	OS	Median	All	0.141	0.687	.003	18	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
STAD	OS	Median	IV	1.000	0.299	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NRF1–DLBC (OS)

Open the DLBC breakdown →